Document is current
Any future updates will be listed below
-
Authors
Rault, A. http://orcid.org/0000-0001-6157-6247
Dolbeault, S. http://orcid.org/0000-0003-4363-2502
Terrasson, J. http://orcid.org/0000-0001-6036-1762
Bouleuc, C. http://orcid.org/0000-0003-0451-7720
Cottu, P. http://orcid.org/0000-0001-6434-3932
Piperno-Neumann, S. http://orcid.org/0000-0001-9915-2810
Rodrigues, M. http://orcid.org/0000-0002-5443-0802
Vaflard, P. http://orcid.org/0000-0002-4710-6895
Brédart, A. http://orcid.org/0000-0002-1864-5371
- License Information
-
More Information
Article History
Received: 29 January 2024
Accepted: 19 August 2024
First Online: 28 August 2024
Declarations
:
: Reference no for ethical approval: ID-RCB: 2019-A01713-54). All patients provided signed informed consent. The study, for which the acronym is helping patients communicate with oncologists when cancer treatment resistance occurs (HECTOR), is registered as NCT04118062 in ClinicalTrials.gov.
: All participants (patients and clinicians) signed an informed consent for study participation and any communication or report of the study results.
: The authors declare that they have no competing interests.
